Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Fibersense, Sernova, Uniqure, Vygon, Xaga.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Arvinas, Assertio, Bayer, Bpgbio, GuideAI, Insight Molecular, Livanova, Perfuse, Pfizer, Rigel, Zydus.
Biopharma and med-tech companies raising money in public or private financings, including: Adaptive, Airs, Bioaffinity, Chugai, Dyne, Gero, Neogenomics, Roche, Sophia, Triveni, Vedana, Wise.
Details were scant, but Biogen Inc. snagged a portfolio of early stage immunology-focused candidates by way of an acquisition deal for Raythera Inc. that could total as much as $1 billion.
Med-tech M&A value through the first five months of 2026 reached $62.98 billion, the highest total for the period since 2022’s $84.13 billion and a dramatic step up from 2025’s $22.4 billion and 2024’s $21.86 billion over the same stretch.
J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment.
RSS
